Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Sosei Group ( (JP:4565) ) is now available.
Nxera Pharma has licensed a G protein-coupled receptor-targeted program to a newly founded independent spin-out backed by a leading international life sciences investment firm, taking an equity stake in the new company. The structure gives Nxera potential milestone and royalty income while allowing the NewCo to lead development and capital raising.
Under the agreement, Nxera retains certain rights to develop and commercialize the asset in Japan and selected Asia-Pacific markets, preserving its regional growth strategy. The company is also considering participation in the NewCo’s planned Series A round, and is reviewing the transaction’s impact on its 2026 financial results, with further disclosures to follow if required.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing specialty medicines for patients with unmet medical needs in Japan and globally. It operates an agile commercial business in Japan and the broader Asia-Pacific region, leveraging its NxWave GPCR structure-based drug discovery platform and partnerships with major pharma and biotech groups to advance an extensive pipeline.
Average Trading Volume: 871,503
Technical Sentiment Signal: Sell
Current Market Cap: Yen77.65B
For detailed information about 4565 stock, go to TipRanks’ Stock Analysis page.